

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM509328

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ALCON RESEARCH, LTD.		12/20/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Eyevance Pharmaceuticals LLC		
Street Address:	777 Taylor Street, Suite 1050		
City:	Fort Worth		
State/Country:	TEXAS		
Postal Code:	76102		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1960827	VEXOL	
CORRESPONDENCE DATA			
Fax Number:	7037161180		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	703-716-1191		
Email:	eteas@gbpatent.com		
Correspondent Name:	Jeffrey H. Handelsman		
Address Line 1:	Greenblum & Bernstein, P.L.C.		
Address Line 2:	1950 Roland Clarke Place		
Address Line 4:	Reston, VIRGINIA 20191-1411		
NAME OF SUBMITTER:	Jeffrey H. Handelsman (Ref.: T57197)		
SIGNATURE:	/Jeffrey H. Handelsman/		
DATE SIGNED:	02/08/2019		
Total Attachments: 4			
source=Executed Assignment - VEXOL#page1.tif			
source=Executed Assignment - VEXOL#page2.tif			
source=Executed Assignment - VEXOL#page3.tif			
source=Executed Assignment - VEXOL#page4.tif			

OP \$40.00 1960827

TRADEMARK ASSIGNMENT

This Trademark Assignment ("*Trademark Assignment*") is made and entered into as of December 20, 2018, by and between Alcon Research, Ltd., a corporation organized under the laws of Delaware located at 6201 South Freeway, Fort Worth, Texas 76134 ("*Assignor*"), and Eyevance Pharmaceuticals LLC, a Delaware limited liability company having its principal address at 777 Taylor Street, Suite 1050, Ft. Worth, Texas 76102 ("*Assignee*" and, together with *Assignor*, the "*Parties*" and each, a "*Party*").

RECITALS

WHEREAS, Assignor and Assignee have entered into a certain an Asset Purchase and License Agreement dated December 20, 2018 between the Assignor, Novartis AG, Basel, Switzerland and the Assignee (the "*Agreement*"); and

WHEREAS, pursuant to the Agreement, Assignor has agreed to, among other things, sell, assign, transfer, convey and deliver to Assignee its entire right, title and interest in, to and under the trademark, (the "*Mark*") set forth on the attached Schedule 1, together with the goodwill associated therewith.

ASSIGNMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, transfers, conveys and delivers to Assignee and its successors and assigns, Assignor's entire right, title and interest in and to the Marks set forth on Schedule 1, together with the goodwill associated therewith, and any and all accounts, contract rights, warranties, litigation claims and rights, including the right to sue for and collect upon all claims for profits and damages as a result of past infringement, if any, and other general intangibles of Assignor related to any of the Marks.

This Assignment is executed for the purposes of evidencing and confirming the transfer of the Marks to the Assignee as provided in the Agreement. Nothing contained in this Assignment is intended to modify any of the provisions of the Agreement as they relate to the Marks, including any of the representations, warranties, covenants or indemnities set forth in the Agreement. In the event of any conflict between this Assignment and the Agreement, the Agreement shall prevail.

Assignor further agrees that it shall on the date hereof and from time to time thereafter, at the request and expense of Assignee, perform or cause to be performed such acts and execute, acknowledge and deliver at the request of Assignee, such documents as may reasonably be required to evidence or effectuate the sale, conveyance, assignment, transfer and delivery to Assignee of the Marks or for the performance by Assignor of any of its obligations hereunder.

[Signature page follows]


IN WITNESS WHEREOF, the Parties have caused this Trademark Assignment to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.

ASSIGNOR

ASSIGNEE

Alcon Research, Ltd.

Eyevance Pharmaceuticals LLC

By: 

By: _____

Name: Martin Bechtold

Name: _____

Title: Adviser

Title: _____

IN WITNESS WHEREOF, the Parties have caused this Trademark Assignment to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.

ASSIGNOR

Alcon Research, Ltd.


By: _____

Name: _____

Title: _____

ASSIGNEE

Eyevance Pharmaceuticals LLC

By:  _____

Name: JERRY ST. PETER

Title: CEO & Director

<

SCHEDULE 1

1. US Marks

Trademark	Country	Serial No.	Filing Date	Reg. No.	Reg. Date
VEXOL	US	74479305	1/13/1994	1960827	3/5/1996